Accelsiors CRO

The future of clinical trials in the U.S. is being shaped by a few key trends. Among them, the increasing use of Real-World Evidence (RWE) and the growing emphasis on diversity and inclusivity stand out. RWE is now pivotal in regulatory decision-making, especially in supporting drug approvals and post-market studies. Furthermore, the FDA is making significant strides to ensure that clinical trial populations are more representative, fostering inclusivity across trials.    At Accelsiors, we're at the forefront of these changes, not just following them. We are here to make the change you so much desire. Whether you're navigating the complexities of RWE or striving to improve diversity in your studies, we have the expertise to support your goals.    Learn more about our services: >> https://lnkd.in/dP2HBvhb     #ClinicalTrials #ClinicalResearch #Biopharma #RealWorldEvidence

The #ESMO Clinical Practice Guidelines on HIV-associated lymphomas provide comprehensive recommendations for the diagnosis, treatment, and management of lymphomas in patients living with HIV. Accelsiors recognizes and embraces the ongoing changes in scientific, methodological, practical, and patient-focused aspects of oncology trials. >> https://lnkd.in/dDyyEZuh Emphasizing the importance of a multidisciplinary approach, we aim to optimize patient outcomes and revolutionize cancer therapy. Let us support you on your journey to stay at the forefront of advancements in oncology. >> https://lnkd.in/dnC_K_3p #ESMO2024 #clinicaltrials #oncology

The WHO published a call for readiness in diagnostic and vaccine manufacturing due to the rise of #MPOX globally.    To underpin our commitment to rapid development in emergencies, we have first-hand experience with vaccines, infectious diseases, and COVID-19 studies from during the pandemic under our belt. Accelsiors has been at the forefront of COVID-19 since the early outbreak of the pandemic, further improving and optimizing our state-of-art technologies and implementing elements of remote, central, and risk-based monitoring.    As we believe our work speaks for us, contact us at [email protected] to learn how our extensive experience in vaccines and infectious diseases can help your clinical studies stay at the forefront of public health challenges. >> https://lnkd.in/dgA9D5wi #monkeypox #healthcare #clinicaltrials #clinicalstudies

𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗔𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 Recent discussions in the oncology field underscore the crucial role of biosimilars in making life-saving cancer treatments more accessible and affordable. With over 60 cancer biosimilars approved by the European Medicines Agency and the FDA, the landscape of oncology treatment is rapidly evolving. As global cancer cases are projected to surge by 77% by 2050, the need for efficient, cost-effective therapies has never been more urgent. We are committed to advancing oncology clinical trials that not only bring innovative therapies to market but also ensure that these treatments are accessible to those who need them most. Our expertise in biosimilar clinical trials is helping to drive down costs while maintaining the highest standards of safety and efficacy. Together, we can turn the tide against cancer by bridging the gap between innovation and accessibility.    Discover how our expertise in biosimilars and oncology can elevate your clinical trial! >> https://lnkd.in/dtgXSjVm >> https://lnkd.in/dDyyEZuh  Reach out to us today and tell us more about your ideas. Email us at [email protected] or message us right here for a quick response! #Biosimilars #Oncology #ClinicalTrials #Innovation

𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗼𝗳 𝗶𝘁𝘀 𝗸𝗶𝗻𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁!   The FDA recently approved a novel oncology treatment targeting a rare type of cancer, showcasing the ongoing innovation in cancer therapy. This approval is expected to pave the way for more targeted therapies, particularly in niche oncology markets.    The use of gene therapy in cancer treatment of metastatic synovial sarcoma is undeniably going to have a global influence on future gene therapy oncology clinical trials.     Have a look at our SPARK focusing on the importance of appointing a US FDA Agent when working in the United States and dealing with the FDA.    Download our SPARK >> https://lnkd.in/dzP-z8Nh     Reach out to [email protected] to get the support you need when registering your product in the US.     #Oncology #ClinicalTrials #Innovation #FDAApproval 

Exciting developments in the U.S. biosimilar market! With biosimilars gaining momentum, the potential to reduce drug costs by over $100 billion in the next five years is within reach.     As a CRO with deep expertise in biosimilar clinical trials, Accelsiors is perfectly positioned to support your next study.     Discover how our tailored services can optimize your trial outcomes >> https://lnkd.in/dtgXSjVm     Explore the latest news and trends with us. Follow the link to our source: https://lnkd.in/drrhjw4X  #clinicaltrials #clinicalresearch #biosimilars #biosimilarmarket

𝗛𝗼𝘄 𝟰 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗔𝗿𝗲 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗖𝗼𝗻𝘁𝗶𝗻𝗲𝗻𝘁  In a strategic move to enhance cancer care across Europe, All.Can and the EFPIA Oncology Platform have joined forces to promote evidence-based discussions on implementing the EU Cancer Screening Recommendation in Belgium, Italy, Romania, and Spain. These efforts are crucial for enhancing cancer screening programs and improving early diagnosis. As we approach the #ESMO24 in September, we’re closely following oncology advancements to align our services with the latest developments. Our commitment to supporting the development of new therapies remains unwavering. Stay tuned as we continue to explore how new initiatives and insights shape the future of oncology. Discover our oncology page for more information on our capabilities >> https://lnkd.in/dDyyEZuh  For any further information, get in touch!   #clinicalresearch #Oncology #ESMO #CancerCare

𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗗𝗮𝘁𝗲: #ESMO24   The ESMO Congress 2024 is just around the corner, happening from September 13-17 in Barcelona!    As we reflect on the progress made over the past year, let's take this opportunity to discuss the latest advancements in oncology and sharing our continued commitment to improving patient outcomes. At Accelsiors, we're excited to engage with the global oncology community, explore innovative research, and collaborate on new solutions. Stay tuned for updates and insights from the congress!   In the meantime, check out the congress calendar to plan your visit and explore key sessions. >> https://lnkd.in/eytECTz8   Contact us to discuss how we can advance oncology together. >> https://lnkd.in/dnC_K_3p #clinicaltrials #oncology #ESMO #oncologyresearch

We proudly introduce the Accelerant™ to improve the success of rare disease clinical trials. This solution is applied across all our clinical research studies. By integrating Accelerant™, we ensure knowledge and compliance, quality, patient perspectives, speed, agility, state-of-the-art technologies, and cost-effectiveness in our trials. Learn more about how we're advancing rare clinical trials worldwide: https://lnkd.in/dx7TDCYC If you have any questions, feel free to email us at [email protected] or send us a message here on LinkedIn. #ClinicalTrials #RareOncology #PatientRecruitment #eclinicalsolutions

#ESMO24 brings interesting news! One of the abstracts this year focuses on the promising results of PD-L1xVEGF bispecific antibodies. This innovative class of therapies could transform how we approach immunotherapy, potentially offering new hope for patients with challenging cancers like 1L TNBC, RCC, and CRC. While we track the progress of these groundbreaking studies, we're also exploring how the microbiome might influence patient responses to advanced treatments. Understanding the interplay between new therapies and the microbiome could unlock new strategies for personalized care. Dive into how the microbiome impacts clinical trials and treatment advances! >> https://lnkd.in/dv2cHEFF Planning to be at #ESMO24? Feel free to email us at [email protected] to arrange a meeting. #ESMO2024 #guthealth #microbiome #clinicalresearch Source: https://lnkd.in/dHgef-MC